Technology and Products

For its first project, EMERCell is developing a generic cell immunotherapy NK-based to be used in synergy with monoclonal antibodies (MAbs) to treat refractory patients in oncology. This new and innovative drug therapy called NK-001 consists of allogeneic Natural Killer (NK) cells which are produced ex vivo according to a patented process.

NK lymphocytes present natural cytotoxicity and specific cytotoxicity in association with MAbs (Antibody-Dependent Cell Cytotoxicity (ADCC)) and are known for their natural immunology surveillance of cancers.

NK cells being considered as highly potent effectors, two NK-based therapeutic strategies exist:

  • Regulating endogenous NK activity, that needs sufficient quantities of properly activable NK cells.
  • Infusing exogenous NK cells to the patient for which full industrialization with production of frozen batches to treat several dozens of patients is rarely reached.

EMERCell NK-001 solution is an optimized active product, with low incidence of endogenous immune system state, consisting of highly activated & alloreactive allogeneic NK cells. The process allows full industrialization using the same source of NK cells for all patients, and producing high quantities of cells to treat dozens of patients with one batch.

Product development and use


Banked UCBs


Patented production process


Generic frozen NK-001 cells


MAb + thawed NK-001 infusion

Inside the step 4 :

MAb + NK-001 cytoxicity

EMERCell technology advantages

A NK-based mature cell immunotherapy generic product used in synergy with monoclonal antibodies to treat refractory patients in oncology

Immunotherapy to help natural body defenses

Mature cell therapy to supply immune-defective patients with highly active effector cells

Highly activated NK cells-based to have a poorly toxic but highly potent effector

Generic product to be used for many patients & many pathologies

Product acting in synergy with monoclonal antibodies to specifically target different pathologies

Strengths of EMERCell technology

Competitive advantages

check No genetic modification

check Generic therapeutic tool to treat different pathologies

check Weak toxicity and genetic instability risks

check Decreased variability

Optimal activity conditions

check Weak incidence of endogenous immune system

check Highly activated NK cells

check Alloreactive allogeneic NK cells

check High MAb receptor expression

Full industrialization

check Availability of biological raw material

check High quantity of produced cells

Industrial Property

March 2014

PCT for NK-001 production process:

October 2015

PCT for NK-001 + mAb:

October 2016

Continuation-in-part application of
PCT/EP2016/071470 n° US 15/458,680